Vidium Animal Health and Torigen Pharmaceuticals Partner to Increase Accessibility of Advanced Cancer Care for Canine Patients

Animal Health Companies Join Forces to Give Vets Nationwide More Options for Treating Cancer in Dogs

PHOENIX, October 11, 2022 /PRNewswire-PRWeb/ — Vidium Animal Health today announced its partnership with Torigen Pharmaceuticals, an animal health biologics company, to bring genomic testing and precision medicine to more veterinarians. By opening the use of personalized precision medicine to the veterinary market, Vidium and Torigen are giving specialists and general veterinarians more options to advance the care of dogs with cancer.

Vidium’s genomics-based diagnostic products leverage the latest scientific knowledge available to provide critical information about a dog’s cancer. The company’s leading genomic diagnostic test, SearchLight DNAⓇ, uses next-generation sequencing to identify important mutations in 120 relevant cancer genes. Knowing the genetic fingerprint of a tumor can help in the diagnosis and prognosis of cancer and inform treatment decisions. Vidium also offers a world-renowned specialist pathology team to support disease diagnosis and treatment planning in small and large animals.

Torigen’s expert sales team will now include SearchLight DNA alongside the company’s personalized cancer immunotherapies in its precision medicine portfolio. When current treatment options aren’t suitable for pets with cancer, Torigen offers a different solution. Using part of the patient’s own tumor, Torigen’s lab prepares a personalized vaccine, harnessing the patient’s immune system to fight the cancer.

The management of canine cancer is becoming more and more accessible and precise with these diagnostic and therapeutic tools. Working with veterinarians across the country, Vidium and Torigen are helping expand options for the pets we love.

“By leveraging Torigen’s sales team to provide veterinarians with a suite of advanced precision cancer diagnostic tools, we can offer veterinary teams a unique combination of genomics, pathology and oncology expertise to expand their options and help improve outcomes for their patients,” comments David HaworthDVM, PhD, President and Co-Founder of Vidium.

“We are delighted to be working with the Vidium team,” adds Ashley Kalinauskas, founder and CEO of Torigen. “The combination of the company’s diagnostic tests and precision medicine expertise, coupled with our targeted cancer therapy, will provide veterinarians and their clients with more cancer treatment options. I am excited to leverage our dedicated sales force to deliver value to veterinary clinics across the country. »

ABOUT VIDIUM ANIMAL HEALTH:
Vidium Animal Health, a subsidiary of Translational Genomics Research Institute (TGen), is committed to advancing the understanding of disease to give companion animals the fullest lives possible. The company provides diagnostic tests for veterinary oncologists, general practitioners and pet owners, and is passionate about unraveling the genetic components of common and complex diseases, including cancer. Vidium has been built on an impeccable scientific foundation and is led by a skilled and experienced team with deep veterinary and clinical genomic roots. For more information, visit: vidiumah.com. Follow Vidium on Facebook, LinkedIn and Twitter@vidiumah.

ABOUT TGEN, A CITY OF HOPE AFFILIATE:
Situated at Phoenix, Arizona, Translational Genomics Research Institute (TGen) is a nonprofit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening illnesses: CityofHope.org. This precision medicine affiliation allows the two institutes to complement each other in research and patient care, with City of Hope providing an important clinical setting to advance the scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes, and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit). Doctors and scientists at TGen work to unravel the genetic components of common and complex rare diseases in adults and children. By working with collaborators in the scientific and medical communities around the world, TGen makes a substantial contribution to helping our patients through the efficiency and effectiveness of the translation process. For more information, visit: tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen.

ABOUT TORIGEN PHARMACEUTICALS:
Torigen is an animal health biologics company dedicated to helping pets with cancer and other unmet medical needs in veterinary medicine. With over 50% of all dogs over the age of 10 dying from cancer, Torigen is focused on providing affordable and accessible cancer care solutions for all pets. Torigen recognizes the pivotal role pets play in our families and is committed to extending the lives of pets despite a diagnosis of cancer.
For more information about Torigen, please visit http://www.torigen.com. Follow Torigen on Facebook, LinkedIn and Instagram.

Media Contact

Jean KallassyTorigen Pharmaceuticals, 860-519-9956, [email protected]

SOURCETorigen Pharmaceuticals

Boyd S. Abbott